Inovio Pharmaceuticals, Inc.

NASDAQ:INO

Biotechnology

Healthcare
$1.71 -0.90%

-$0.01 today

Market cap
$118.15M
Beta
1.49
P/E (TTM)
-8.9
EPS (TTM)
-$0.12
52W Low $1.03High $2.98

Volume 9.92M

Average 2.73M

Cash Flow

Check whether earnings turn into cash.

Operating Cash Flow

-$88.63M

FY 2025 · Annual

Investing Cash Flow

$14.04M

FY 2025 · Annual

-86.5% YoY

Financing Cash Flow

$53.05M

FY 2025 · Annual

+3.1% YoY

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(303.66M)(279.82M)(135.12M)(107.25M)(84.95M)
Depreciation & Amortization4.73M5.5M3.5M3.13M2.99M
Deferred Income Tax04.03M(32.05K)00
Stock-Based Compensation26.34M22.56M11.07M6.6M3.76M
Change in Working Capital50.35M19.83M(10.26M)(2.66M)(9.22M)
Accounts Receivables11.03M(3.71M)9.33M1.21M0
Inventory00000
Accounts Payables26.14M32.61M(45.99M)(3.37M)(6.42M)
Other Working Capital13.18M(9.07M)26.4M(504.04K)(2.8M)
Other Non-Cash Items6.53M11.69M6.47M(3.88M)(1.21M)
Operating Cash Flow(215.71M)(216.22M)(124.37M)(104.08M)(88.63M)
Capital Expenditures(1.23M)(969.15K)(320.9K)(487.83K)(285.7K)
Acquisitions (Net)0(2M)6.22M00
Purchases of Investments(348.95M)(248.53M)(203.48M)(54.14M)(4.95M)
Sales of Investments174.84M361.08M284.93M158.64M19.27M
Other Investing Activities00059.32K0
Investing Cash Flow(175.34M)109.59M87.36M104.07M14.04M
Debt Repayment000(16.42M)0
Common Stock Issued209.44M82.96M5.46M68.31M53.16M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities2.06M(1.11M)(466.65K)(420.8K)(110.78K)
Financing Cash Flow211.5M81.84M5M51.48M53.05M
Effect of Forex Changes(30.13K)(25.56K)(3.92K)32.4K0
Net Change in Cash(179.58M)(24.81M)(32.02M)51.5M(21.54M)
Free Cash Flow(216.94M)(217.18M)(124.69M)(104.56M)(88.92M)

Free Cash Flow

Net Income to FCF bridge

FY2025

= Net Income-$84.9M
+ D&A$3.0M
+ Stock-Based Comp$3.8M
+ Deferred Tax$0
- Working Capital-$9.2M
- Other Non-Cash-$1.2M
= Operating Cash Flow-$88.6M
- Capex-$285.7K
= Free Cash Flow-$88.9M

Analysis

FY2025 free cash flow is -$88.9M. FCF conversion is 104.7% of net income. Operating cash flow was -$88.6M, with capex of -$285.7K. The largest bridge item is Working Capital at -$9.2M.

Recent Filings

Recent regulatory filings

FilingDescriptionDate
FWPFWP filingNov 6, 2026
424B5424B5 filingNov 6, 2026
8-KCurrent reportNov 5, 2026
SC 13G/ASC 13G/A filingNov 5, 2026
424B5424B5 filingNov 5, 2026

Does INO generate free cash flow?

Inovio Pharmaceuticals, Inc. (INO) generated -$88.92M of free cash flow in fiscal 2025.

How much operating cash flow does INO produce?

Operating cash flow was -$88.63M, before capital expenditures of $285,698.00.